Skip to content
DataLookout
Menu

NCT04658147

Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 13 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Oct 28, 2026 Show 4 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 33 words
    • Secondary endpoints: 12 to 14
    • Study title shortened, about 6 words
  2. Minor Primary completion date changed from estimate of Dec 1, 2025 to Sep 2, 2025
    • Study completion date: Dec 1, 2026 to Jun 1, 2030
    v19
  3. Minor Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 20 to confirmed 31
    • Site details revised at 2 of 2 sites
    v17
  4. Notable Primary completion date: Jun 1, 2025 to Dec 1, 2025
    • Study completion date: Jun 1, 2026 to Dec 1, 2026
    v16
  5. Minor Study sites: 1 to 2v14
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Site contact updatedv10
  2. Minor Start date changed from estimate of Jun 2021 to May 28, 2021
    • Site contact updated
    v8
  3. Minor Primary completion date: Jun 2025 to Jun 1, 2025
    • Study completion date: Jun 2025 to Jun 1, 2026
    v7
  4. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v6
  5. Notable Start date: Apr 2021 to Jun 2021
    • Primary and study completion dates: Apr 2025 to Jun 2025
    v5
  6. Notable Start date: Feb 2021 to Apr 2021
    • Primary completion date: Feb 2025 to Apr 2025
    • Study completion date: Feb 2026 to Apr 2025
    v3
  7. Minor Study title shortened, about 1 wordv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Patients Precluded From Surgery
Timeframe: Up to 2 months

Secondary (14)

Number of Participants Experiencing Grade 3 or Above Study Drug-related Adverse Event (AE)
Number of Participants Who Obtain R0 Resection
Number of Evaluable Patients With Pathologic Response to Treatment
Objective Response Rate (ORR) at 8 Weeks Using Response Evaluation Criteria for Solid Tumors (RECIST 1.1).
Overall Survival (OS) Rate at 12 Months
Show 9 moreShow less
Overall Survival (OS) Rate at 18 Months
Overall Survival (OS) at 3 Years
Overall Survival (OS) at 5 Years
Disease Free Survival (DFS) Rate at 12 Months
Disease Free Survival (DFS) at 18 Months
Disease Free Survival (DFS) at 3 Years
Disease Free Survival (DFS) at 5 Years
Overall Survival (OS)
Disease Free Survival (DFS)

Arms and interventions

Arm A - NivolumabExperimental

Participants receive Nivolumab only.

Arm B - Nivolumab and RelatlimabExperimental

Participants receive Nivolumab and Relatlimab.

Drugs: Nivolumab, Relatlimab

Sites

2 sites in 1 country